Literature DB >> 3964788

Endometrial and pituitary responses to the steroidal antiprogestin RU 486 in postmenopausal women.

A Gravanis, G Schaison, M George, J de Brux, P G Satyaswaroop, E E Baulieu, P Robel.   

Abstract

The effects of the antiprogestin RU 486 on the human endometrium were investigated. Seventeen postmenopausal women were injected with estradiol (E2) benzoate (0.625 mg/day) for 15 days. Progesterone (P) (25 mg/day) and/or RU 486 (100 or 200 mg/day) were given to groups of 2-3 women during the last 6 days of E2 benzoate treatment. Serial blood samples were drawn for the measurement of plasma E2, P, and LH and FSH. An endometrial biopsy was performed on the last day of treatment, and processed for histology or for assays of DNA polymerase alpha, E2-dehydrogenase (E2DH), and P receptor (PR). Treatment with E2 benzoate alone resulted in a marked decrease of plasma gonadotropins; in those patients who received either P, RU 486, or both, in addition to E2 benzoate, the concentrations of plasma LH and FSH were further decreased to premenopausal levels. In absence of glycerol, the affinity of RU 486 for the endometrial PR (Kd = 0.8 nM) was higher than that of P (Kd = 1.2 nM). Glycerol decreased markedly the affinity of RU 486, whereas the affinity of P for the PR was unchanged. RU 486 had negligible affinity for plasma transcortin. Either P or RU 486, but not both together, induced secretory changes in the endometrium as determined from histologic sections of tissue biopsies. Either P or RU 486 decreased DNA polymerase alpha and increased E2-DH activities in the endometrium. Unexpectedly, when P and RU 486 were given together. E2-DH activity remained at the level found in E2-treated women. In vitro cultures of proliferative endometrium treated with the synthetic progestagen R 5020 or with RU 486 also had increased E2-DH activity; RU 486 counteracted R 5020 effects. We conclude that, contrary to previous results with experimental animals, the anti-P RU 486 has some progestomimetic activity in humans under specific conditions. Paradoxically, when given together with P, RU 486 lost most of its progestomimetic activity in the endometrium and behaved as a pure antagonist.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3964788     DOI: 10.1210/jcem-60-1-156

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

Review 1.  Proven and potential clinical applications of mifpristone (RU486).

Authors:  Irving M Spitz
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

Review 2.  Contragestion by antiprogestin RU 486: a review.

Authors:  E E Baulieu; A Ulmann; D Philibert
Journal:  Arch Gynecol Obstet       Date:  1987       Impact factor: 2.344

3.  In vivo evidence against the existence of antiprogestins disrupting receptor binding to DNA.

Authors:  K Delabre; A Guiochon-Mantel; E Milgrom
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

4.  Antioxidant: a new role for RU-486 and related compounds.

Authors:  S Parthasarathy; A J Morales; A A Murphy
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

Review 5.  Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  R N Brogden; K L Goa; D Faulds
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

6.  Antiprogestagen RU486 prevents the LH-dependent decrease in the serum concentrations of inhibin in the rat.

Authors:  M Tébar; C Bellido; J T Uilenbroek; J E Sánchez-Criado
Journal:  Cell Mol Neurobiol       Date:  1996-06       Impact factor: 5.046

7.  Estradiol and progesterone-induced slowing of gonadotropin-releasing hormone pulse frequency is not reversed by subsequent administration of mifepristone.

Authors:  Christopher R McCartney; Susan K Blank; John C Marshall
Journal:  Endocrine       Date:  2009-07-16       Impact factor: 3.633

Review 8.  Antiprogestin pharmacodynamics, pharmacokinetics, and metabolism: implications for their long-term use.

Authors:  G R Jang; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1997-12

9.  Interaction of newly synthesized antiprogesterone ZK98299 with progesterone receptor from human myometrium.

Authors:  A D'souza; I N Hinduja; S Kodali; V K Moudgil; C P Puri
Journal:  Mol Cell Biochem       Date:  1994-10-12       Impact factor: 3.396

Review 10.  Mifegyne (mifepristone), a new antiprogestagen with potential therapeutic use in human fertility control.

Authors:  B Couzinet; G Schaison
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.